Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974286 | 1.00 | TSHR (0.42) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL406707 | 1.00 | TSHR (0.42) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11974278 | 1.00 | TSHR (0.42) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11974282 | 1.00 | TSHR (0.42) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11974287 | 0.97 | TSHR (0.44) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL14199137 | 0.97 | TSHR (0.44) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11974290 | 0.97 | TSHR (0.44) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11974288 | 0.97 | TSHR (0.44) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11974284 | 0.97 | TSHR (0.44) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL14944901 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267630-A1 | CLASS-AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-21 | — | — | US | disclosed |
| US-9540317-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-10-29 | — | — | US | disclosed |
| US-8716344-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUE, INC. (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | TSHR 3987/4885TDP1 2992/4885LMNA 1808/4885 |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | TSHR 3987/4885TDP1 2992/4885LMNA 1808/4885 |
| US-20170267630-A1 | CLASS-AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | TSHR 3987/4885TDP1 2992/4885LMNA 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.